We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

A second opinion

23 September 2020 By Robert Cyran

The company, which helps consumers find discounts on prescription meds, jumped 40% on its debut. True, the market is so hot that such a pop is now ho-hum. Still, GoodRx’s $18 bln valuation is a bet that a system riddled with middlemen is here to stay, however the election goes.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)